Zobrazeno 1 - 10 of 275 pro vyhledávání: '"J. W. J. Bijlsma"'
1
Akademický článek
The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial
Autor: M. S. Jurgens, M. Safy-Khan, M. J. H. de Hair, J. W. J. Bijlsma, P. M. J. Welsing, J. Tekstra, F. P. J. G. Lafeber, E. H. Sasso, J. W. G. Jacobs, on behalf of the Society for Rheumatology research Utrecht
Publikováno v: Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Objectives The CAMERA-II trial compared two tight-control, treat-to-target strategies, initiating methotrexate with prednisone (MTX+pred) or MTX with placebo (MTX+plac), in early RA-patients. The multi-biomarker disease activity (MBDA) blood
Externí odkaz: https://doaj.org/article/56fda2b3974a492dbf353dccefa2737e
Zobrazit plný text záznamu
2
Akademický článek
A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients.
Autor: S C Nair, P M J Welsing, I Y K Choi, J Roth, D Holzinger, J W J Bijlsma, J M van Laar, D M Gerlag, F P J G Lafeber, P P Tak
Publikováno v: PLoS ONE, Vol 11, Iss 3, p e0152362 (2016)
Measurement of MRP8/14 serum levels has shown potential in predicting clinical response to different biological agents in rheumatoid arthritis (RA). We aimed to develop a treatment algorithm based on a prediction score using MRP8/14 measurements and
Externí odkaz: https://doaj.org/article/244baf6716a743a3939bbbc47b15a0cc
Zobrazit plný text záznamu
4
SAT0046 Transcript-protein associations in early ra patients achieving sustained drug-free remission after treatment with tocilizumab
Autor: Michelle E A Borm, J. W. J. Bijlsma, J.M. van Laar, Xavier M Teitsma, J. W. G. Jacobs, Attila Pethö-Schramm, Arno N. Concepcion, F.P.J.G. Lafeber
Publikováno v: Saturday, 16 JUNE 2018.
Background In disease modifying anti-rheumatic drug (DMARD)-naive early rheumatoid arthritis (RA) patients, we previously identified networks of differentially co-expressed genes associated with achieving sustained drug-free remission (sDFR).[1 A bet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::77284c68e591d80d4593938ff730f6c3
https://doi.org/10.1136/annrheumdis-2018-eular.3467
Zobrazit plný text záznamu
6
FRI0040 Development and validation of clinical predictors for inadequate response to treat-to-target methotrexate therapy in newly diagnosed ra patients
Autor: J.M. van Laar, Johanna M. W. Hazes, P.M.J. Welsing, Xavier M Teitsma, J. W. J. Bijlsma, Attila Pethö-Schramm, Angelique E. A. M. Weel, P.H. de Jong, J. W. G. Jacobs, F.P.J.G. Lafeber, Michelle E A Borm
Publikováno v: FRIDAY, 15 JUNE 2018.
Background In new-onset rheumatoid arthritis (RA), therapy should be aimed at achieving sustained remission according to current guidelines, in which methotrexate (MTX) is recommend to be included in the initial treatment strategy. However, a large p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::693758f2aaab2b40917bbf98fa2cdeb6
https://doi.org/10.1136/annrheumdis-2018-eular.3463
Zobrazit plný text záznamu
9
SAT0218 Effect of tocilizumab in DMARD-NAÏVE early rheumatoid arthritis patients on health-related quality of life: results of the U-ACT-EARLY trial
Autor: J. W. G. Jacobs, Xavier M Teitsma, J.M. van Laar, P.M.J. Welsing, F.P.J.G. Lafeber, Michelle E A Borm, J. W. J. Bijlsma, Attila Pethö-Schramm
Publikováno v: Poster Presentations.
Background Tocilizumab (TCZ), a humanized interleukin-6 receptor inhibitor, has been shown effective in suppressing symptoms of rheumatoid arthritis (RA). In U-Act-Early, a significantly greater proportion of patients with early RA who initiated TCZ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::139e0c522cdb6dd74842d6abb335bc44
https://doi.org/10.1136/annrheumdis-2017-eular.2190
Zobrazit plný text záznamu
10
SAT0508 Lack of a clear disease modifying activity of celecoxib in treatment of end-stage knee osteoarthritis: a randomized observer blinded clinical trial
Autor: T.N. de Boer, J.M. van Laar, A.A. Polak, S.C. Mastbergen, A. M. Huisman, K. Coeleveld, EM Van Helvoort, J. W. J. Bijlsma, Fjpg Lafeber
Publikováno v: Poster Presentations.
Background Several studies suggest that celecoxib has beneficial effects on degenerated cartilage (1, 2). Together with effects on synovial tissue and bone, celecoxib was postulated to have disease modifying osteoarthritic drug (DMOAD) activity. Obje
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84ede5f01e6b28cb01d2107169686a31
https://doi.org/10.1136/annrheumdis-2017-eular.1454
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje